Rationale and design of the randomized, multicenter, Cilostazol for restenosis (CREST) trial
Key result
Cilostazol may reduce in-stent coronary restenosis after stent implantation, as suggested by earlier studies and currently being evaluated in the CREST trial.
Why the study?
Does cilostazol improve minimal luminal diameter and prevent restenosis in patients following uncomplicated stent implantation for de novo coronary artery stenosis?
Population
Patients following uncomplicated stent implantation for de novo coronary artery stenosis
Comparison
Cilostazol added to clopidogrel and aspirin vs Placebo added to clopidogrel and aspirin
Design
RCT, randomized, double-blind
Follow-up
6 months
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change post-stent regimens; leaves open cilostazol benefit on restenosis pending CREST.
Structured PICO
Does cilostazol improve minimal luminal diameter and prevent restenosis in patients following uncomplicated stent implantation for de novo coronary artery stenosis?
P
Population
Patients following uncomplicated stent implantation for de novo coronary artery stenosis
I
Intervention
Cilostazol added to clopidogrel and aspirin
C
Comparator
Placebo added to clopidogrel and aspirin
O
Outcome
Minimal luminal diameter (MLD) of the first lesion stented after 6 monthssurrogate
Cite This Study
Douglas et al. (2003) studied this question. Cilostazol may reduce in-stent coronary restenosis after stent implantation, as suggested by earlier studies and currently being evaluated in the CREST trial.